Dupixent CTCL Skin Cancer Lawsuit
Harding Mazzotti, LLP is investigating cases of patients who developed Cutaneous T-cell lymphoma (CTCL) after being prescribed Dupixent (dupilumab).
GET YOUR FREE CASE REVIEW
"*" indicates required fields
By clicking the Submit button, you consent to being contacted by Harding Mazzotti, LLP at the number and/or email provided, and consent to receiving SMS/text messages. Message and Data Rates may apply. You can STOP messaging by sending STOP and get more help by sending HELP. You acknowledge that submitting this form and the information contained therein does not establish an attorney client relationship, and therefore, you will not rely upon this information as legal advice. By submitting this form, you understand that any information received in response to this questionnaire is general information for which there will be no charge.
Content Reviewed by:
- Date Last Updated: March 27, 2026
On This Page
What is Dupixent?
Dupixent, known generically as dupilumab, is an injectable biologic medicine that was approved by the FDA in 2017. It has been prescribed to treat several inflammatory conditions, including:
- Atopic dermatitis (eczema)
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Bullous pemphigoid
Dupixent is marketed as a groundbreaking treatment, and it has swiftly become a success for its primary manufacturers, Sanofi and Regeneron. Nevertheless, new research links the use of Dupixent to an increased risk of developing cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin lymphoma.
What is Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-cell lymphoma, or CTCL, is a type of lymphoma that predominantly affects the skin. It can be difficult to treat and is often not curable. There are two subtypes of CTCL:
- Mycosis fungoides, which grows slowly and primarily affects the skin
- Sezary syndrome, which is less common but more aggressive, affects both the skin and the blood
What are the Symptoms of CTCL?
Because CTCL often resembles eczema or other skin conditions, it frequently goes undiagnosed or is misdiagnosed in the early stages. Common symptoms include:
- Lasting skin rashes or lesions
- Patches or plaques that look like eczema or psoriasis
- Excessive itching or burning skin
- Enlarged or swollen lymph nodes
- Large areas of redness or swelling on the body
- Hair Loss
Is Dupixent Linked to CTCL?
Studies indicate a link between Dupixent and the development of CTCL. In fact, in early 2024, the FDA labeled CTCL as a “potential signal of a serious risk” related to Dupixent and stated that regulatory action was under consideration.
Multiple scientific studies suggest that patients using Dupixent may have an increased risk of developing CTCL. A study published in the Journal of the American Academy of Dermatology in 2019 showed that a patient experienced an acceleration of CTCL symptoms while using dupilumab. Importantly, experts have warned that Dupixent can mask early signs of CTCL or hasten its progression, potentially delaying diagnosis and treatment because CTCL can resemble eczema. Patients and doctors might initially believe the drug is treating a flare-up, while the lymphoma continues to advance.
An April 2024 study (Hasan et al., 2024) investigated whether individuals with atopic dermatitis treated with dupilumab (Dupixent) had a higher risk of developing CTCL compared to those who did not use the drug. One model from the study found that people who took dupilumab had a 300% higher risk of developing CTCL than those who did not.
Another study in August 2024 (Mandel et al., 2024) employed a method similar to the first study by Hasan et al. They matched patients by age, race, and sex, and found that individuals with atopic dermatitis treated with dupilumab had a 350% higher risk of developing CTCL compared to those not receiving the treatment.
In 2025, Ma et al. examined the risk of blood cancers in patients with asthma treated with dupilumab compared to those using a different common asthma drug combination. For patients who had taken their medications for at least 16 weeks, the risk was more than 14 times higher for those treated with dupilumab compared to the group who did not.
Who may qualify for a Dupixent lawsuit?
You or someone you love may qualify for a Dupixent lawsuit if:
- You were prescribed Dupixent (dupilumab) for eczema, asthma, COPD, bullous pemphigoid, or other related conditions
- You were later diagnosed with Cutaneous T-cell lymphoma (CTCL), specifically the subtypes mycosis fungoides or Sezary syndrome
What compensation may be available?
If you or a loved one developed CTCL following the use of Dupixent, you may be entitled to compensation for:
- Medical costs, including cancer treatments, hospital bills, medications, and more
- Lost Wages and reduced earning capacity
- Pain and suffering compensation for the physical pain, emotional trauma, and reduced quality of life that come with a CTCL diagnosis.
- Wrongful death claims for families of patients who passed away from Dupixent-related CTCL
- Punitive damages that penalize Sanofi and Regeneron if they are found to have recklessly disregarded patient safety
If you or a loved one was prescribed Dupixent and later developed CTCL, you may be entitled to compensation. Please contact the defective drug lawyers at Harding Mazzotti, LLP today for a free case evaluation. Click, Chat, or call 1800LAW1010 24/7 for a free consultation. You pay nothing unless we win.
injured in an accident?
Get your free case review today
After filling out a form, our team will be in touch to schedule a free consultation to discuss your case.
For a quick response, call us at (844) 446-1044
